Tuesday, October 4, 2022


Biotechnology News Magazine

Futura Provides FDA Regulatory and Commercial Update for MED3000

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

MED3000: Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to provide an update on FDA regulatory processes and commercial activities for MED3000.

US regulatory progress

Last week Futura met with the FDA for a pre-submission meeting to define and confirm the detail of the work required for OTC classification in the USA for MED3000, the Company’s breakthrough fast acting clinically proven treatment for erectile dysfunction (“ED”).


The Company is pleased to confirm that the FDA has agreed to the design of the non-clinical, Human Factors Study, subject to the issue of the final meeting minutes. The study will test the ability of subjects to self-diagnose their ED, correctly select the product based on label information and test their ability to correctly use the product without supervision of a doctor. The FDA has asked for a minimum of 15 subjects to complete the study.

As previously communicated, comprehensive planning and preparation activities including active site selection are well underway for the commencement of FM71, the required confirmatory clinical study, with the first patient dosing expected during Q3 2021 targeting completion of the FM71 study and Human Factors study for Q2 2022.  US OTC marketing authorisation remains on track for approval for MED3000 in Q1 2023.

Commercial progress

Manufacturing scale up and capacity to meet projected demand is progressing well in conjunction with commercial out-licensing agreements covering the remaining major regions and countries of the world with a number of interested parties.  As previously outlined, Futura expects to be able to update shareholders further during the remainder of 2021 as it looks to target the launch of MED3000 during 2022.

MED3000, is a topical gel which utilises our proprietary technology DermaSys®, developed specifically for the treatment of erectile dysfunction (“ED”). It is a fast-acting topical treatment which has the potential to be a highly differentiated product by addressing significant unmet needs in the ED market.

James Barder, Chief Executive of Futura Medical commented: “Subject to receipt of the final meeting minutes we are pleased that the requirements to enable an OTC application for MED3000 have been clarified with the FDA.  In addition, we remain focused on preparation and execution of the FM71 study with the first patient dosing expected later this year. The USA remains the largest market opportunity globally for ED treatments and we are making steady progress on attaining approval for MED3000 in the region.”




Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine